Pathways for Patient-centered Diagnosis and Management of Endometriosis-associated Deep Dyspareunia

Endometriosis-related Pain Clinical Trial

Official title:

Pathways for Patient-centered Diagnosis and Management of Endometriosis-associated Deep Dyspareunia: A Pilot Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04370444
• Other study ID #: H19-00294
• Status: Completed
• Phase: N/A
• Start date: March 10, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: December 2023
• Source: BC Women's Hospital & Health Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the acceptability and effectiveness of two tools that may help address the management of deep dyspareunia: 1) A phallus length reducer (PLR, brand name: Ohnut), consisting of 4 interconnected silicone rings worn externally over the penetrating object to reduce pain with deep penetration by allowing adjustable limitation of penetration depth, and 2) A vaginal insert for at home self-assessment of the extent and severity of deep dyspareunia.

Description:

Background: Endometriosis is a gynecological condition characterized by the abnormal growth of endometrial like tissue outside of the uterus. The condition affects approximately 10% of reproductive-age females and can cause various types of pain, including chronic pelvic pain and deep dyspareunia (pelvic pain with deep sexual intercourse). Research has shown that individuals with endometriosis and dyspareunia have significantly reduced sexual quality of life, lower self-esteem, and impaired sexual function. Qualitative research has also demonstrated that many individuals with dyspareunia feel guilty about their pain, and often continue to engage in intercourse even when the pain is severe.

Aims and Hypotheses:

1. To measure the reduction in deep dyspareunia observed among people using the PLR with their partner. The investigators hypothesize that the PLR will be associated with a reduction in self-reported deep dyspareunia scores among participants randomized to the PLR intervention, compared to participants randomized to the waitlist control group. The measured reduction in deep dyspareunia will be used to power a future definitive trial.

2. To assess the acceptability of the phallus length reducer (PLR) for participants with endometriosis and their partners. The investigators hypothesize that both partners will indicate the PLR is acceptable on the self-reported questionnaire.

3. To explore whether an at-home assessment of dyspareunia is an acceptable and valid alternative to clinical measures. The investigators hypothesize that the at-home assessments of dyspareunia will be acceptable to participants and will yield results that are highly correlated with questionnaire-based and clinical assessments of this pain.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 31, 2021
• Est. primary completion date: October 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 49 Years

Eligibility

Inclusion Criteria:

Patient

• 19 to 49 years of age

• Monogamous sexual partnership

• Sexually active or not sexually active due to deep dyspareunia

• Self-reported deep dyspareunia score = 4/10

• Sexual partner who is willing to participate

• Willing to engage in penetrative sex at least once during the duration of the study

Partner

• 19 years of age or older

• Sexually active with a patient participant who has consented to participate in this study

Exclusion Criteria:

Patient

• Superficial dyspareunia score = 4/10 (This is a potentially confounding variable; the PLR is not expected to affect introital pain)

• Current use of a PLR

• Inability to complete English-language questionnaires

• GAD-7 score = 15

• PHQ-9 score = 15

• Intense fear/anxiety in anticipation of, during, or as a result of vaginal intercourse

Partner

• Current use of a PLR

• Inability to complete English-language questionnaires

Related Conditions & MeSH terms

• Dyspareunia
• Dyspareunia Deep
• Endometriosis
• Endometriosis-related Pain

Intervention

Device:
• Phallus Length Reducer
Phallus Length Reducer

Other:
• Self-assessment of dyspareunia
Use of a vaginal insert to self assess dyspareunia

Locations

Country	Name	City	State
Canada	BC Women's Hospital	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
BC Women's Hospital & Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability of the phallus length reducer (PLR)	Acceptability of the PLR as measured via questionnaire using a 5 point likert scale (1 = most negative/ worst/ strongly disagree, 5 = most positive/ best/ strongly agree)	After 6 weeks of using the PLR
Secondary	Severity of dyspareunia	Self reported on an 11-point numeric rating scale (0 being no pain, 10 being worst pain imaginable)	Measured at baseline, before and after 6 weeks of using the PLR
Secondary	Change in sexual function	Change in sexual function as measured by Female Sexual Function Index (FSFI). This a brief, self-administered questionnaire to assess key dimensions of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and are scored from 1 to 5 (with 1 being the lowest report of desire and 5 being the highest).	Measured at baseline, before and after 6 weeks of using the PLR
Secondary	Change in sexual distress	Change in sexual distress as measured in Female Sexual Distress Scale-Revised (FSDS-R) This is a self-administered measure of female personal distress associated with sexual dysfunction. There are 13 questions. The range for each question is 0 (Never) to 4 (Always).	Measured at baseline, before and after 6 weeks of using the PLR
Secondary	Change in level of general anxiety (GAD-7)	Change in level of general anxiety as measured using the General Anxiety Disorder - 7 questionnaire. There are 7 questions. The range for each question is 0 (not at all) to 4 (nearly every day).	Measured at baseline, before and after 6 weeks of using the PLR
Secondary	Change in level of general depression (PHQ-9)	Change in level of general depression as measured using the Patient Health Questionnaire- 9 questionnaire. There are 9 questions. The range for each question is 0 (not at all) to 4 (nearly every day).	Measured at baseline, before and after 6 weeks of using the PLR
Secondary	Acceptability of self-measurement of dyspareunia	Acceptability of self-measurement of dyspareunia will be measured via questionnaire using 5 point likert scale (1 = most negative/ worst/ strongly disagree, 5 = most positive/ best/ strongly agree)	After patient self-measurement of dyspareunia is complete (2 times during study)
Secondary	Validity of self-measurement of dyspareunia	Dyspareunia score from the self-measurement will be compared to records of dyspareunia scores from physician performed pelvic exams. (11 point scale, 0 being no pain, 10 being worst pain imaginable)	Assessment and questionnaire administered 2 times, each one week apart, during the first 4 weeks of the study (to be assessed at week 2 and 3 of participant's menstrual cycle, which may vary)
Secondary	Feasibility - Recruitment	The proportion of potentially eligible individuals who were successfully contacted by the study team (response rate); the proportion of contacted individuals who were ineligible, declined to participate, and consented; the number of couples enrolled per month of active recruitment (recruitment rate).	Up to 6 months
Secondary	Feasibility - Retention	The proportion of enrolled participants who completed the study (retention rate).	Up to 6 months
Secondary	Feasibility - Intervention Fidelity	To evaluate protocol adherence we documented: the proportion of sexual encounters using the Ohnut per couple in the intervention group during the intervention period (intervention fidelity) and the proportion of missing data.	Up to 6 months